Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling

Pharm Res. 2014 Dec;31(12):3390-403. doi: 10.1007/s11095-014-1429-9. Epub 2014 Jun 12.

Abstract

Purpose: Neutropenia is a severe adverse-event of chemotherapeutics. Neutrophils (ANC) are mainly regulated by granulocyte colony stimulating factor (G-CSF). The aim was to characterize the dynamics between endogenous G-CSF and ANC over time following chemotherapy.

Methods: Endogenous G-CSF and ANC were monitored in forty-nine breast cancer patients treated with sequential adjuvant 5-fluorouracil-epirubicin-cyclophosphamide and docetaxel.

Results: During treatment courses ANC was transiently decreased and was reflected in an endogenous G-CSF increase, which was well described by a semi-mechanistic model including control mechanisms; when G-CSF concentrations increased the proliferation rate increased and the bone maturation time reduced for ANC. Subsequently, ANC in the circulation increased leading to increased elimination of G-CSF. Additionally, a non-specific elimination for G-CSF was quantified. The ANC-dependent elimination contributed to 97% at baseline and 49% at an ANC of 0.1 · 10(9)/L to the total G-CSF elimination.

Conclusion: The integrated G-CSF-myelosuppression model captured the initial rise in endogenous G-CSF following chemotherapy-induced neutropenia and the return to baseline of G-CSF and ANC. The model supported the self-regulatory properties of the system and may be a useful tool for further characterization of the biological system and in optimization of chemotherapy treatment.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / complications
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism*
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / pharmacokinetics
  • Cyclophosphamide / therapeutic use
  • Epirubicin / adverse effects
  • Epirubicin / pharmacokinetics
  • Epirubicin / therapeutic use
  • Female
  • Fluorouracil / adverse effects
  • Fluorouracil / pharmacokinetics
  • Fluorouracil / therapeutic use
  • Granulocyte Colony-Stimulating Factor / metabolism*
  • Humans
  • Leukocyte Count
  • Middle Aged
  • Neutropenia / chemically induced*
  • Neutrophils
  • Prospective Studies

Substances

  • Granulocyte Colony-Stimulating Factor
  • Epirubicin
  • Cyclophosphamide
  • Fluorouracil

Supplementary concepts

  • FEC protocol